INDUSTRY × Observational × Carcinoma, Renal Cell × Clear all TraveraRTGx
Completed
72 enrolled
CABOCARE
Active not recruiting
224 enrolled
REPLICA
Active not recruiting
150 enrolled
DP-04
Recruiting
100 enrolled
ADONIS
Completed
554 enrolled
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
Completed
494 enrolled
BASECAMP-1
Recruiting
200 enrolled
ELEPHAS-02
Recruiting
416 enrolled
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
Completed
105 enrolled 11 charts
NEUTROFLOW
Not yet recruiting
600 enrolled
PRCC
Recruiting
150 enrolled
CARAT
Recruiting
1,930 enrolled
ORACLE
Recruiting
2,020 enrolled
Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
Completed
13 enrolled 14 charts
DESCENT-1
Enrolling by invitation
400 enrolled
Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy
Completed
499 enrolled
WITNESS
Active not recruiting
600 enrolled
AUR87A
Completed
280 enrolled
Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Completed
388 enrolled 20 charts
J-DART2
Completed
171 enrolled 36 charts
A Multicenter Cancer Biospecimen Collection Study
Recruiting
1,650 enrolled
A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan
Completed
286 enrolled
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
Terminated
106 enrolled 21 charts
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
Completed
481 enrolled 14 charts
ROOT
Completed
167 enrolled
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Withdrawn
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
Completed
1,112 enrolled 16 charts
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Completed
1,050 enrolled 9 charts
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
Completed
355 enrolled 23 charts
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
Completed
376 enrolled 17 charts
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
Completed
347 enrolled
OPTIMISE
Terminated
77 enrolled 34 charts
A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients
Completed
135 enrolled
TRACE
Terminated
246 enrolled 18 charts
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
Completed
48 enrolled 36 charts
Axitinib Therapy Management Study
Withdrawn
Delving Into Participation Trends in Renal Cell Carcinoma Studies
Not yet recruiting
500 enrolled
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Terminated
20 enrolled
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
Completed
1,674 enrolled 17 charts
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Completed
102 enrolled 23 charts
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Completed
1,769 enrolled 12 charts
BRC
Recruiting
1,000 enrolled
Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
Completed
1,349 enrolled 24 charts
CASSIOPE
Completed
689 enrolled
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)
Completed
57 enrolled 35 charts
PARADIGM
Recruiting
800 enrolled
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
Completed
81 enrolled
"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
Completed
157 enrolled 41 charts
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
Unknown
200 enrolled
A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal
Completed
105 enrolled